Trial Profile
Metro-PD1: a Phase I/II Trial Evaluating Anti-PD1 (Nivolumab) in Combination With Metronomic Chemotherapy in Children and Teenagers With Refractory/Relapsing Solid Tumors
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Nivolumab (Primary) ; Vinblastine (Primary)
- Indications Ependymoma; Ewing's sarcoma; Glioma; Lymphoma; Neuroblastoma; Rhabdomyosarcoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms Metro-PD1
- 28 Feb 2024 Status changed from recruiting to suspended for interim analysis.
- 06 Jan 2024 Results (n=16) assessing feasibility and safety of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors published in the European Journal of Cancer
- 30 Jun 2023 Lower age limit of 4 years has been removed from inclusion criteria.